David U'Prichard

Dec 21, 2006

Premium

Drug developer CoGenesys said that David U’Prichard has been appointed to the company’s board of directors.

U’Prichard currently sits on the boards of Invitrogen and SR Pharma, the parent firm of Atugen.

Note to Readers: This is the last issue of RNAi News to publish in 2006. The next issue of the newsletter will appear on Thursday, Jan. 4.

RNAi

Breaking News

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.